Cholangiocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Biliary Tract Cancer (386)

Gallbladder Cancer (45)

Biliary Tract Cancer (386)

Gallbladder Cancer (45)

›

FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	FGFR2-ARHGAP24 fusion	Cholangiocarcinoma	TT-00434 Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) TT-00434 Sensitive : C3 ESMO Asia 2023 - 1wk	TT-00434 Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week TT-00434 Sensitive : C3 ESMO Asia 2023 - 1 week - (New C3)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
MSI-H/dMMR	Cholangiocarcinoma	MSI-H/dMMR	Cholangiocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2	FGFR inhibitor Sensitive: A2 - Guideline FGFR inhibitor Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B
HER-2 expression	Cholangiocarcinoma	HER-2 expression	Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B	TT-00420 Sensitive: B - Late Trials TT-00420 Sensitive : B
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
RET fusion	Cholangiocarcinoma	RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
BRCA2 mutation	Cholangiocarcinoma	BRCA2 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Cholangiocarcinoma	BRCA1 mutation	Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Cholangiocarcinoma	NTRK1 fusion	Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
BRAF V600	Cholangiocarcinoma	BRAF V600	Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
NTRK2 fusion	Cholangiocarcinoma	NTRK2 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Cholangiocarcinoma	NTRK3 fusion	Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1

Cholangiocarcinoma

Associations(218)

Associations
(218)